Related references
Note: Only part of the references are listed.10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects
Jonatan Barrera-Chimal et al.
NATURE REVIEWS NEPHROLOGY (2022)
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and their Combination in Patients with Chronic Kidney Disease: A Randomized Cross-Over Clinical Trial
Michele Provenzano et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Peter Rossing et al.
DIABETES CARE (2022)
Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis
Shunichiro Tsukamoto et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2022)
Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin
Aya Saiki et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2022)
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
Darren K. McGuire et al.
JAMA CARDIOLOGY (2021)
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
Takayuki Yamada et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
David Z. I. Cherney et al.
DIABETOLOGIA (2021)
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Niels Jongs et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers
Clinical Diabetes (2021)
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
The global burden of chronic kidney disease
Paul Cockwell et al.
LANCET (2020)
Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure
Milton Packer
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial
Megumi Oshima et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension
Keith C. Ferdinand et al.
CIRCULATION (2019)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
Sadayoshi Ito et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
Carol Pollock et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Jae Hyun Bae et al.
SCIENTIFIC REPORTS (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
Paola Fioretto et al.
DIABETES OBESITY & METABOLISM (2018)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Ralph A. DeFronzo et al.
NATURE REVIEWS NEPHROLOGY (2017)
Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples
Richard D. Riley et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples
Richard D. Riley et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Albuminuria and Endothelial Dysfunction in Patients with Non-Diabetic Chronic Kidney Disease
Meng-Jie Huang et al.
MEDICAL SCIENCE MONITOR (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature
Zachary Belden et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients
Sergei I. Petrykiv et al.
DIABETES OBESITY & METABOLISM (2017)
Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials
Xinfang Xie et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
H. J. L. Heerspink et al.
DIABETES OBESITY & METABOLISM (2016)
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
David Cherney et al.
DIABETOLOGIA (2016)
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
Gemma Currie et al.
BMC NEPHROLOGY (2016)
Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis
S. Takahashi et al.
JOURNAL OF HUMAN HYPERTENSION (2016)
Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial
Sawako Kato et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2015)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Ilkka Tikkanen et al.
DIABETES CARE (2015)
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial
Katsuyuki Ando et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
Kunihiro Matsushita et al.
LANCET (2010)
Blood pressure lowering for the prevention and treatment of diabetic kidney disease
Merlin C. Thomas et al.
DRUGS (2006)
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy - A randomized, double-masked, cross-over study
K Rossing et al.
DIABETES CARE (2005)
Rates of hyperkalemia after publication of the randomized aldactone evaluation study
DN Juurlink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the detection of ischemia in asymptomatic diabetics-brachial artery reactivity study)
GI Papaioannou et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy:: The LIFE study
K Wachtell et al.
ANNALS OF INTERNAL MEDICINE (2003)
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus - A blood pressure-independent effect
G Viberti et al.
CIRCULATION (2002)
Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity
HL Hillege et al.
JOURNAL OF INTERNAL MEDICINE (2001)
Relation of blunted dilation of the brachial artery in insulin-dependent diabetes mellitus to microalbuminuria
P Poredos et al.
AMERICAN JOURNAL OF CARDIOLOGY (2000)
Arterial hypertension, microalbuminuria, and risk of ischemic heart disease
JS Jensen et al.
HYPERTENSION (2000)
Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients
JCN Chan et al.
KIDNEY INTERNATIONAL (2000)
Share Paper
